Samantha Pearce's departure as Chief Commercial Officer of Jazz Pharmaceuticals plc was reported; the filing names no successor. As of November 6, 2026, Jazz Pharmaceuticals plc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 29, 2026 to October 9, 2026, naming 1 departure (Form 8-K, October 9, 2026).
Who owns Jazz Pharmaceuticals plc?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Jazz Pharmaceuticals plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Jazz Pharmaceuticals plc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-29 to 2026-10-09. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Jazz Pharmaceuticals plc files it.
Also on the record for Jazz Pharmaceuticals plc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 8.6% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 7.4% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.04% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Jazz Pharmaceuticals plc now and the warning signs.
Free to see. No signup.
Keep reading
More on Jazz Pharmaceuticals plc and the records around it.
Jazz Pharmaceuticals plc elsewhere on the record
Companies that share a holder
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Jazz Pharmaceuticals plc
Get an email when Jazz Pharmaceuticals plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Jazz Pharmaceuticals plc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Jazz Pharmaceuticals plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Jazz Pharmaceuticals plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-09 | Out | Chief Commercial Officer | 8-K, 2026-10-09 | ||
| 2026-05-29 | Reported | not named in the filing | 8-K, 2026-05-29 |
Who leads Jazz Pharmaceuticals plc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Commercial Officer: Samantha Pearce, departure reported (filed 2026-10-09). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Jazz Pharmaceuticals plc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Commercial Officer at Jazz Pharmaceuticals plc, with the record behind each one.
Find candidates like Chief Commercial Officer at Jazz Pharmaceuticals plcEvery change, in the filing's words
Departing: Samantha Pearce, Chief Commercial Officer
On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the "Company" ), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier of the selection and appointment of her successor or by June 30, 2027.
- The Company plans to commence a formal search process to identify Ms. Pearce's successor, which will consider both internal and external candidates.
Reported
On May 25, 2026, Anne O'Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the "Company") 2026 annual meeting of shareholders, has informed the board of directors (the "Board") that she will not stand for re-election.
- Consistent with the Company's commitment to ongoing board refreshment and board effectiveness, the Board will continue to evaluate its composition and to facilitate orderly board succession processes.
- Ms. O'Riordan's decision was not the result of any dispute or disagreement with the Company or the Company's Board on any matter relating to the operations, policies or practices of the Company.
Tools for this story
Each opens in a new tab, filled in for Jazz Pharmaceuticals plc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.